Hikal gains on passing ANVISA`s GMP audit for Jigani unit
Hikal is currently trading at Rs. 377.90, up by 1.90 points or 0.51% from its previous closing of Rs. 376.00 on the BSE.
The scrip opened at Rs. 381.00 and has touched a high and low of Rs. 381.90 and Rs. 376.20 respectively. So far 11550 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 464.50 on 02-Dec-2024 and a 52 week low of Rs. 294.45 on 18-Jun-2024.
Last one week high and low of the scrip stood at Rs. 386.00 and Rs. 370.95 respectively. The current market cap of the company is Rs. 4657.07 crore.
The promoters holding in the company stood at 68.85%, while Institutions and Non-Institutions held 9.49% and 21.66% respectively.
Hikal has successfully passed the Brazilian Health Regulatory Agency’s (ANVISA) Good Manufacturing Practices (GMP) audit for its manufacturing unit located at Jigani in Bengaluru, Karnataka. The inspection, carried out by ANVISA, Brazil GMP, was for multiple API’s which occurred from April 14 to April 18, 2025.
Hikal is engaged in R&D, manufacturing and marketing of fine chemicals for the Pharmaceutical and Agrochemical industries.
